Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Nov;86(3):529–531. doi: 10.1111/j.1476-5381.1985.tb08927.x

Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.

E Melamed, M B Youdim
PMCID: PMC1916713  PMID: 3877535

Abstract

N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) is toxic to dopaminergic neurones in several mammalian species including mice. Combined treatment with phenylethylamine prevented in mice the long-term (30 days post-treatment) dopamine depletions in striatum induced by MPTP. Phenylethylamine, a naturally-occurring specific substrate of monoamine oxidase (MAO) type B, probably protects against effects of MPTP by competitively inhibiting the oxidative conversion of MPTP to its toxic metabolite N-methyl-4-phenylpyridinium ion catalysed by MAO-B.

Full text

PDF
529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antelman S. M., Edwards D. J., Lin M. Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulating action. Brain Res. 1977 May 27;127(2):317–322. doi: 10.1016/0006-8993(77)90548-0. [DOI] [PubMed] [Google Scholar]
  2. Boyce S., Kelly E., Reavill C., Jenner P., Marsden C. D. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochem Pharmacol. 1984 Jun 1;33(11):1747–1752. doi: 10.1016/0006-2952(84)90344-7. [DOI] [PubMed] [Google Scholar]
  3. Chiba K., Trevor A., Castagnoli N., Jr Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984 Apr 30;120(2):574–578. doi: 10.1016/0006-291x(84)91293-2. [DOI] [PubMed] [Google Scholar]
  4. Chiueh C. C., Markey S. P., Burns R. S., Johannessen J. N., Pert A., Kopin I. J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol. 1984 Apr 20;100(2):189–194. doi: 10.1016/0014-2999(84)90221-8. [DOI] [PubMed] [Google Scholar]
  5. Hallman H., Lange J., Olson L., Strömberg I., Jonsson G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem. 1985 Jan;44(1):117–127. doi: 10.1111/j.1471-4159.1985.tb07120.x. [DOI] [PubMed] [Google Scholar]
  6. Hefti F., Melamed E., Wurtman R. J. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther. 1981 Apr;217(1):189–197. [PubMed] [Google Scholar]
  7. Heikkila R. E., Hess A., Duvoisin R. C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984 Jun 29;224(4656):1451–1453. doi: 10.1126/science.6610213. [DOI] [PubMed] [Google Scholar]
  8. Heikkila R. E., Manzino L., Cabbat F. S., Duvoisin R. C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984 Oct 4;311(5985):467–469. doi: 10.1038/311467a0. [DOI] [PubMed] [Google Scholar]
  9. Langston J. W., Irwin I., Langston E. B., Forno L. S. Pargyline prevents MPTP-induced parkinsonism in primates. Science. 1984 Sep 28;225(4669):1480–1482. doi: 10.1126/science.6332378. [DOI] [PubMed] [Google Scholar]
  10. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., Herkenham M. A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 1984 Oct 4;311(5985):464–467. doi: 10.1038/311464a0. [DOI] [PubMed] [Google Scholar]
  11. McQuade P. S. Analysis and the effects of some drugs on the metabolism of phenylethylamine and phenylacetic acid. Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(4-6):607–614. doi: 10.1016/0278-5846(84)90022-8. [DOI] [PubMed] [Google Scholar]
  12. McQuade P. S., Wood P. L. The effects of beta-phenylethylamine on tyramine and dopamine metabolism. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(4-6):755–759. doi: 10.1016/0278-5846(83)90060-x. [DOI] [PubMed] [Google Scholar]
  13. Mytilineou C., Cohen G. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science. 1984 Aug 3;225(4661):529–531. doi: 10.1126/science.6610939. [DOI] [PubMed] [Google Scholar]
  14. Parsons B., Rainbow T. C. High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase. Eur J Pharmacol. 1984 Jul 13;102(2):375–377. doi: 10.1016/0014-2999(84)90274-7. [DOI] [PubMed] [Google Scholar]
  15. Rainbow T. C., Parsons B., Wieczorek C. M., Manaker S. Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase. Brain Res. 1985 Mar 25;330(2):337–342. doi: 10.1016/0006-8993(85)90694-8. [DOI] [PubMed] [Google Scholar]
  16. Raiteri M., Cerrito F., Cervoni A. M., del Carmine R., Ribera M. T., Levi G. Studies on dopamine uptake and release in synaptosomes. Adv Biochem Psychopharmacol. 1978;19:35–56. [PubMed] [Google Scholar]
  17. Salach J. I., Detmer K., Youdim M. B. The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. Mol Pharmacol. 1979 Jul;16(1):234–241. [PubMed] [Google Scholar]
  18. Yang H. Y., Neff N. H. Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther. 1973 Nov;187(2):365–371. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES